Graphical Abstract Highlights d The majority of high-grade serous ovarian cancers arise from fallopian epithelia d A subset of proliferative-type tumors likely arise from ovarian epithelial cells d Super enhancers dysregulate transcription factor expression during tumorigenesis d SOX18 induces an epithelial-to-mesenchymal transition in fallopian tube epithelia
In Brief
Lawrenson et al. profile gene expression and active chromatin in 200 ovarian and fallopian epithelial isolates and implement machine learning to demonstrate that most high-grade serous ovarian cancers (HGSOCs) derive from fallopian tube epithelial cells, but a subset may originate from ovarian epithelia. SOX18 induces mesenchymal features to drive early neoplasia in fallopian tube precursors.
INTRODUCTION
Invasive epithelial ovarian cancers are a heterogenous group of tumors comprising several major histological subtypes: high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous. High-grade serous ovarian cancer (HGSOC) is the most common subtype, comprising around two-thirds of all invasive cases. Our understanding of the cellular origins of HGSOC and key transcription factor networks deregulated during HGSOC development has been restricted by the lack of substantial molecular profiling data for the putative precursor tissues, specifically fallopian tube secretory epithelial cells (FTSECs) and ovarian surface epithelial cells (OSECs).
Historically, HGSOCs were thought to arise from OSECs, an atypical epithelial cell type with mesothelial features and inherent phenotypic plasticity and heterogeneity (Kruk and Auersperg, 1992; Park et al., 2018) . However, examples of early-stage ovarian carcinoma arising from OSECs in vivo are rare. The discovery of occult carcinomas in the fallopian tubes of BRCA1 and BRCA2 mutation carriers supports an alternative hypothesis that the fallopian epithelium harbors the cell-of-origin for HGSOC Leeper et al., 2002; Medeiros et al., 2006; Paley et al., 2001; Piek et al., 2001) . Subsequent studies have shown that a substantial proportion of all HGSOC cases in non-BRCA1/2 mutation carriers arise from the fallopian tube and, more specifically, the tubal secretory epithelial cells (Gilks et al., 2015; Kindelberger et al., 2007; Labidi-Galy et al., 2017) . However, there is no evidence of fallopian tube involvement in other cases, suggesting that other cell types may be precursors for a proportion of HGSOCs.
The goal of this study was to investigate the hypothesis that FTSECs and OSECs both represent cells of origin of HGSOC. To do this, we compared the molecular relationships between OSECs, FTSECs, and HGSOCs based on transcriptomic and epigenomic profiles. We first used machine learning to identify transcriptional signatures of disease origins by using data from 114 OSECs, 74 FTSECs, and 394 HGSOCs. We then performed chromatin immunoprecipitation sequencing (ChIP-seq) to map active chromatin in OSECs, FTSECs, and HGSOCs and characterize tissue-specific super-enhancer landscapes. Finally, we integrated ChIP-seq and transcriptomic data to identify transcription factors SOX18, ELF3, and EHF as putative drivers of transcriptional deregulation in HGSOC development. Characterizing the exact origins of the HGSOC will be essential for the development of effective tumor prevention and early detection strategies in the future.
RESULTS

Expression Profiling of Putative Ovarian Cancer Precursor Cells
One approach to investigate the cellular origins of cancer is to quantify similarities and differences between molecular signatures of tumors and the proposed tissues of origin (Staub et al., 2010) . This is based on the hypothesis that the molecular blueprint of normal precursor cells is maintained in developing tumors. We performed RNA sequencing (RNAseq) in 74 FTSEC and 114 OSEC short-term cultures established from 132 individuals; OSEC and FTSEC specimens were derived from the same individual in 56 cases Lawrenson et al., 2009) (Table S1 ). To ensure quality control, we performed RNA-seq in duplicate for five samples (one OSEC and four FTSEC specimens), which (n-74) . OSEC samples tend to cluster more tightly together, whereas FTSEC samples show more diffuse clustering. PCA analyses were divided into dimensions 1 and 2 (A) and dimensions 1 and 3 (B). This suggests greater inter-patient heterogeneity between for FTSEC samples. (C) Volcano plot illustrating differential gene expression between OSEC and FTSEC samples. Known cell-type-specific markers for each cell type are indicated. confirmed high correlation of expression profiles across between replicates (Pearson's correlation r = 0.79-0.98) ( Figure S1A ). We found no associations with experimental or epidemiological variables (where available), including sample preparation, patient age, or patient ethnicity (data not shown).
We used principal-component analysis (PCA) to compare expression profiles of OSECs and FTSECs. The two cell types largely stratified according to their molecular profiles (Figures 1A and 1B) . We identified 87 significantly differentially expressed genes (DEGs) between OSECs and FTSECs (absolute log 2 fold change [FC] > 2, p adj = 10 À30 ; Figure 1C ; Table S2 ). These included MUC16 (which encodes ovarian cancer screening marker CA125) and CDH1 (E-cadherin), two genes already known to be differentially expressed between these cell types (Figures 1C and S1B) . We also identified overexpressed genes in OSECs; these included GATA4 (FC = 7.1, p adj = 3.78 3 10 À42 ) and NR5A1 (FC = 6.7, p adj = 2.59 3 10 À39 ) both of which are transcriptional activators potentially involved in the differentiation of OSECs. Differentially expressed genes (DEGs) that are highly expressed in FTSECs compared to OSECs include genes that encode the cell surface or secreted proteins MMP7 (FC = 9.9, p adj = 1.87 3 10 À31 ), CLIC5 (FC = 8.36, p adj = 5.14 3 10 À49 ), TACSTD2 (FC = 8.21, p adj = 1.2 3 10 À42 ), and CFTR (FC = 8.15, p adj = 7.35 3 10 À31 ).
Machine Learning to Predict Cell of Origin for HGSOCs
We applied machine learning algorithms to predict the cell of origin for 394 primary HGSOCs profiled by The Cancer Genome Atlas (TCGA). To correct for differences in read depth and RNA-seq methods between studies, we aligned, batch corrected, and normalized all three datasets-OSEC, FTSEC, and TCGA-together (see STAR Methods). We first defined cell-type-specific signatures of OSECs and FTSECs and then applied a one-class logistic regression (OCLR) methodology, which is particularly well suited to scenarios where a negative class cannot be clearly defined (Sokolov et al., 2016a ). First, we tested the performance of the models in identifying OSECs mixed into an FTSEC background and vice versa. Area under the curve (AUC) statistics generated using a leave-one-out approach indicated that the OCLR models performed with high specificity (average AUC for OSECs = 0.99 and for FTSECs = 0.97). OCLR models provide a score for each sample and for each category, which is rescaled between zero and one, where zero implies no similarity and one implies high similarity.
We applied the OCLR models to HGSOCs to generate an OSEC and FTSEC score for each individual tumor to determine which cell type represents the most likely cell of origin. HGSOC samples were randomized and divided into two equally sized groups (n = 197), designated the training set and the validation set. Each set included similar numbers of the four HGSOC molecular subgroups-differentiated, immunoreactive, mesenchymal, and proliferative-classified by their gene expression signatures (Cancer Genome Atlas Research Network, 2011; Tothill et al., 2008) . In both the training and validation datasets, we observed a greater proportion of HGSOCs with higher FTSEC scores than OSEC scores. In the training set, 103/197 tumors (52%) had an FTSEC score > 0.5, whereas only 20/197 tumors (10%) had an OSEC score > 0.5. In the validation set, 124/197 tumors (63%) and 82/197 tumors (42%) had FTSEC and OSEC scores > 0.5, respectively (Figures 2A and 2B) . Taken together, these data indicate that across the whole dataset, transcriptome signatures of HGSOCs are more similar to those of FTSECs than OSECs, consistent with a large body of data indicating that FTSECs are the most common cell of origin for HGSOC. There was a weak negative correlation between tumor FTSEC and OSEC scores ( Figure S2A ) (Pearson's product-moment correlation = À0.16, p = 0.002). In a PCA performed using all expressed genes, FTSECs cluster more closely to HGSOCs than OSECs ( Figure S2B ). However, 19 tumors (4.8% of cases) had OSEC scores greater than 0.75, indicating they have most likely derived from ovarian surface epithelial cells. Taken together, these data are consistent with the hypothesis that HGSOCs can originate from both FTSECs and OSECs, with FTSECs the most common cell of origin (Eckert et al., 2016; Pothuri et al., 2010; Salazar et al., 1996) .
We also investigated if FTSEC and OSEC scores correlate with clinical and molecular features of HGSOCs. In both the training and validation datasets, mesenchymal-type HGSOCs had significantly higher FTSEC OCLR scores (p adj < 0.02 in the training and validation cohort; Figure 2C ; p adj = 8 3 10 À4 in a meta-analysis of all 394 HGSOCs); patients in this subgroup of HGSOC had the worst survival (Cancer Genome Atlas Research Network, 2011). By contrast, patients with proliferative-type HGSOCs had significantly larger OSEC scores (p adj < 0.001 in the training and validation cohort, p adj = 2 3 10 À4 in a meta-analysis) ( Figure 2D ), indicating that OSECderived tumors are enriched in this molecular subgroup. Finally, we tested for associations between FTSEC and OSEC OCLR scores and patient age, tumor stage, tumor grade, chemoresponse, and debulking status ( Figures S2C and S2D ). We found no significant associations for FTSECs, but tumors with high OSEC scores were associated with older age at diagnosis (p adj = 0.005, normalized enrichment score = 1.6). Higher OSEC score was modestly associated with increased sensitivity to chemotherapy (p adj = 0.03, normalized enrichment score = 1.5) ( Figure S2D ).
FTSEC Super-Enhancer Landscapes Are Conserved in HGSOCs
Epigenomic signatures can also serve as indicators of cell lineage. We used chromatin immunoprecipitation sequencing (ChIP-seq) for H3K27ac to characterize epigenomic landscapes in OSECs (n = 2), FTSECs (n = 2), and HGSOCs (n = 4), and using these data super-enhancer (SE) landscapes, defined as dense clusters of highly active chromatin that typically localize with master regulators of cellular identity (Whyte et al., 2013) . OSECs and HGSOCs had the largest numbers of cell-type-specific SEs (n = 337 and n = 336, respectively). Significantly more SEs were shared between FTSECs and HGSOCs (n = 80) than between OSECS and HGSOCs (n = 37) (odds ratio = 12.9, Fisher's exact test, p < 2.2 3 10 À16 ; Figures 3A and 3B ). Using the transcriptomic data shown in Figure 1 , we verified tissue-specific overexpression of genes proximal to tissue-specific SEs (Figures 3C, 3F, and 3I). The PAX8 transcription factor (TF) was overexpressed in both FTSECs and HGSOCs and coincides with a SE detected in both cell types at this locus; PAX8 is a well-established biomarker that is ubiquitously expressed in FTSECs and is overexpressed in the majority of primary HGSOCs (Cheung et al., 2011; Laury et al., 2011; Mhawech-Fauceglia et al., 2012 ) ( Figure S3 ). Supporting this, using PAX8 ChIP-seq data in ovarian cancer cell lines and FTSECs, we observed PAX8 binding within the PAX8 super enhancer ( Figure S3 ). We also identified candidate genes regulated by SEs in each cell type, including SULT1B1 in OSECs (Figures 3D and 3E ) and the Tripartite Motif Containing 55 (TRIM55) gene in FTSECs ( Figures  3G and 3H ). The SOX18 transcription factor was marked by an SE in HGSOCs but not in normal tissues, and SOX18 was overexpressed in tumors, suggesting this is a SE-driven TF in HGSOC ( Figures 3J and 3K ).
SOX18 Is a Driver of Epithelial-to-Mesenchymal Transition in HGSOC The SOX18 TF has been implicated in angiogenesis and lymphangiogenesis (Duong et al., 2012; Franç ois et al., 2008; Lilly et al., 2017) but has not previously been shown to have a cellautonomous role in HGSOC. We quantified SOX18 gene expression in 13 high-grade serous ovarian cancer cell lines and 3 immortalized FTSEC lines ( Figure 4A ). SOX18 transcript was overexpressed in HGSOC cell lines compared to normal FTSECs (FC = 18.5), indicating that the elevated expression of SOX18 seen in primary tumors ( Figure 3K ) is driven, at least in part, by endogenous tumor epithelial cell expression.
To model the role of SOX18 overexpression in HGSOC development, we ectopically overexpressed SOX18 in a TERTimmortalized FTSEC line (FT282) stably expressing mutant p53 ( Figures 4B, 4C , and S4A). Single-cell RNA-seq analysis was performed to identify transcriptomic changes associated with SOX18 overexpression compared to controls. Graph-based clustering analysis identified 5 main clusters ( Figure S4B ); clusters 1 and 3 were enriched for SOX18-overexpressing cells, whereas cluster 2 was enriched for control cells ( Figure 4D ). Many of the differentially genes in clusters 1-3 were associated with the extracellular matrix and the epithelial-to-mesenchymal transition (EMT), including integrin subunit beta-4 (ITGB4) and fibronectin 1 (FN1). The collection of 263 genes significantly upregulated in SOX18-overexpressing cells (FC > 1.2, p < 0.001) was associated with extracellular matrix organization (p adj = 6.6 3 10 À12 ), non-integrin-membrane-ECM interactions (p adj = 4.0 3 10 À10 ), and wound healing (p adj = 4.7 3 10 À8 ), indicating epithelial differentiation was disrupted following SOX18 overexpression ( Figure 4E ). Consistent with this, SOX18-overexpressing FT282 cells adopted a more mesenchymal cellular morphology and exhibited longer population doubling times compared to controls ( Figures 4F and 4G) . OSECs overexpressing SOX18 did not show the same morphological change, and population doubling times were unaffected ( Figures S4C-S4F ). Mechanical phenotypes of the cells were evaluated using a parallel microfiltration assay, in which more deformable cells pass more readily through 10-mm pores in a polycarbonate membrane in response to applied pressure (Qi et al., 2015) . SOX18-overexpressing FTSECs were significantly more deformable than parental or control cells ( Figure 4H ), consistent with observations that ectopic expression of key EMT transcription factors, SNAI1, SNAI2 or ZEB1, increases the deformability of EOC cells in vitro (p < 0.01, unpaired Student's t test) (Qi et al., 2015) . Indeed, ectopic SOX18 expression in FTSECs induced upregulated expression of mesenchymal markers (CDH2, PRRX1, SNAI1, SNAI2, TWIST1, VIM, and ZEB1) and downregulated expression of epithelial marker CDH1 (Figure 4I) , measured using qRT-PCR. In contrast, EMT gene expression was not affected in OSECs overexpressing SOX18 ( Figure S4 ). In FTSECs, dysregulation of EMT markers was partially rescued by PRRX1 depletion, indicating this factor is in part responsible for the observed EMT, but other factors also likely contribute ( Figure 4J ).
Identifying Drivers of Transcriptional Reprogramming in the Development of HGSOC
To identify additional TFs that may drive transcriptional deregulation during HGSOC development from FTSECs and/or OSECs, we performed a targeted analysis of genes associated with DNA binding, TF activity, and chromatin remodeling. For nine of the most overexpressed transcriptional regulators in HGSOCs ( Figure 5A) , high-quality ChIP-seq data were available from http://cistrome.org. We quantified how many of the most differentially expressed genes in HGSOCs were located near to (within 50 kbp) a factor-specific peak compared to matched random peaks (see STAR Methods). Factor-specific peaks for regulators including SPI1, CTCFL, NFE2, ASCL2, and GRHL2 were more numerous in the vicinity of HGSOC DEGs (p < 10 À30 for a comparison to FTSECs and p < 10 À50 for a comparison to OSECs) than randomly generated matched sets of background peaks (100 iterations, p < 0.01; Figure 5B ,C; genes located close to factor peaks are listed in Tables S3 and S4 ). Binding sites for ELF3, a factor highly expressed in both FTSECs and HGSOCs but lowly expressed in OSECs, were specifically enriched near to genes differentially expressed between FTSECs and HGSOCs (p = 0.009; Figure 5B ), with no evidence of enrichment in the set of genes differentially expressed in the development of HGSOC from OSECs (p = 1; Figure 5C ). Conversely, EHF-binding sites were associated with DEGs in a comparison of HGSOCs to OSECs but not FTSECs (p = 0.009 and p = 0.06, respectively). Notably, both ELF3 and EHF genes are proximal to SEs in HGSOC ( Figure S5 ). Collectively, these factors represent drivers of transcriptional reprogramming in HGSOC, with ELF3 likely to be specific to the transformation of FTSECs, and EHF, a putative driver of HGSOC development from OSECs.
DISCUSSION
The cellular origins of high-grade serous ovarian cancer are debated. Over the last few years, the fallopian tube and, specifically the secretory epithelial cell component (FTSECs), has emerged as the most likely common origin for HGSOCs; but the existing data suggest there may be more than one cell of origin. In this study, we used machine learning to address the hypothesis that HGSOCs have dualistic cellular origins with ovarian surface epithelial cells (OSECs), another precursor cell type. The machine learning approach has been well established as a metric for classifying tumor of unknown origin, based on (C, F, and I) H3K27ac ChIP-seq data were integrated with RNA-seq data for each tissue type. Average gene expression in 114 OSECs, 74 FTSECs, and 394 HGSOCs is shown for regions centered on cell-type-specific SEs; (D, G, and J) representative loci displaying tissue-specific SE deposition for each tissue type; (E, H, and K) boxplots illustrating differential gene expression between tissue types for candidate, cell-type-specific cis-regulated genes. The associated gene consistently displays higher expression in the SE-positive tissue type.
''bulk'' molecular profiling (Flynn et al., 2018; Moran et al., 2016; Staub et al., 2010; Søndergaard et al., 2017) .
The evidence for FTSECs as the major cell of origin of HGSOC is substantial: early-stage lesions in the fallopian tube, particu-larly in the fallopian tube fimbriae, express secretory cell lineage markers and harbor the same TP53 mutations as metastatic tumors Gilks et al., 2015; analyses have identified HGSOC-specific copy number alterations and somatic mutations in serous tubal intraepithelial carcinomas (Labidi-Galy et al., 2017) and find no significant differences in the molecular profiles of HGSOCs associated with STICs and those without (Ducie et al., 2017) . In vitro and in vivo modeling studies also support FTSECs as a major cell of origin for HGSOC Perets et al., 2013; Zhai et al., 2017) , and salpingectomy (surgical removal of fallopian tubes but not the ovaries) can reduce the risk of ovarian cancer by around 35% or more (Falconer et al., 2015) . Historically, OSECs were thought to be the precursor cell type for HGSOC, and there remains significant, and often overlooked, evidence supporting this hypothesis. First, OSECs can express many prominent HGSOC markers, including PAX8 (Adler et al., 2015; Park et al., 2018) . Second, OSECs from women at high risk of ovarian cancer are more committed to an epithelial phenotype and in culture maintain expression of CA125 longer than OSECs from non-high-risk women (Dyck et al., 1996) . Third, occult cancers have been detected in the ovaries of women undergoing prophylactic risk reducing oophorectomy and can occur without evidence of lesions in the fallopian tube (Powell et al., 2005) . Fourth, a recent detailed analysis of almost 60 ovaries documented evidence for metaplasia of ovarian epithelium to a M€ ullerian phenotype, suggesting that adoption of a more fallopian-like morphology may be an early step in the neoplastic transformation of OSECs (Park et al., 2018) .
In the current study, we found greater similarities in transcriptomic signatures between FTSECs and a cohort of almost 400 HGSOCs, supporting FTSECs as the major precursor cell type. Primary HGSOCs can be sub-stratified into 4 different molecular groups based on mRNA expression profiles, and high FTSEC scores were enriched in mesenchymal-type HGSOCs, consistent with previous observations indicating that fallopian-like HGSOCs are associated with poorer clinical outcomes (Merritt et al., 2013) . A small proportion of HGSOCs had transcriptional signatures that were more similar to OSECs, and these OSEClike tumors tended to be of the proliferative molecular subgroup, which have better outcomes. Taken together, these data indicate that different molecular subgroups of HGSOC may derive from different precursor cells and suggest the cell of origin may influence patient outcomes.
Little is known about the key transcription factors (TFs) driving oncogenesis in HGSOC. The most significant TF identified to date is PAX8, which is highly expressed in FTSECs and HGSOCs, moderately expressed in some OSECs, and is functionally involved in disease development (Adler et al., 2015 Cheung et al., 2011; Elias et al., 2016; Kar et al., 2017) . By analyzing epigenomic landscapes annotated from H3K27ac ChIP-seq data, we found that the PAX8 gene locus is marked by a strong SE in both FTSECs and HGSOCs. We also identified SOX18 as one of the few TFs that coincided with a tumor-specific SE, and functional studies found SOX18 to be a regulator of EMT in HGSOC development from FTSECs but not OSECs. SOX18 has established roles in tumor-induced angiogenesis and lymphangiogenesis and is known to be aberrantly expressed in melanoma and gastric, breast, lung, and pancreatic cancers (Duong et al., 2012; Eom et al., 2012; Pula et al., 2013; Saitoh and Katoh, 2002; Zhang et al., 2016) . In gastric cancer, SOX18 expression is correlated with increased lymph node metastasis and worse overall survival (Eom et al., 2012) . Additionally, SOX18 levels in peripheral blood samples of gastric cancer patients are significantly increased compared to healthy controls, suggesting the feasibility of clinically assessing SOX18 levels in patients with cancer. The role of SOX18 in ovarian cancer is not well defined. One study examined SOX18 protein expression in a small cohort of 85 patients and found high SOX18 expression was associated with advanced stage and worse disease specific survival (Pula et al., 2014) . Our finding that SOX18 induces EMT in FTSECs in vitro may indicate that SOX18 plays a role in establishing the mesenchymal signature enriched in FTSEC-like HGSOCs.
In conclusion, this study represents a significant advance on previous studies in both scale and scope of the molecular profiling of putative precursor cell types for high-grade serous ovarian cancer (Merritt et al., 2013) . This represents, considerably, the largest study to profile the transcriptomes of FTSECs and OSECs (188 samples from 135 different individuals in total), which enabled us to derive robust signatures with which to study B C A Figure 5 . Transcriptional Regulators Implicated in HGSOC Development (A) Transcriptional regulators highly expressed in HGSOCs.
(B and C) The number of differentially expressed genes in HGSOCs compared to FTSECs (B) and OSECs (C) that localize with ChIP-seq peaks for each factor (orange) and factor-specific matched random peaks (blue). *p < 0.05, **p < 0.01. the relationships between these putative cells of origin and the different molecular subtypes of HGSOC. As a result, we have been able to provide evidence that both FTSECs and OSECs are likely precursors of this disease, and we note that our conclusions are consistent with those observed in a new mouse model (Zhang et al., 2018) . Moreover, we provide evidence for the role of SOX18 and other transcription factors in the development of HGSOC, which may represent candidate clinical biomarkers and potential therapeutic targets for this disease.
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Growth curves
Cells were plated at 50,000 cells per well of a 6-well plate, in triplicate. An additional triplicate of the parental cell line was treated with absolute methanol to serve as an additional control. Cells were passaged and counted every 3-4 days for > 28 days. Growth curves were performed three times, independently.
PMF assay
The PMF device is assembled using polycarbonate membrane (Isopore, Millipore) with 10 mm pore diameter. Cell suspension (350 mL) at a concentration of 0.5 3 10 6 cells/mL is loaded into each well. Constant air pressure of 2.1 kPa is applied for 20 s using a custombuilt manometer and monitored using a pressure gauge (Noshok Inc., Berea, OH, USA). We determine % retention by collecting the sample suspension remaining in the top well and reading absorbance at 560 nm wavelength of the retained volume using a plate reader (Techan Infinite M1000, Thermo Fisher Scientific). To measure cell number and obtain size distributions, we use an automated cell counter (TC20, BioRad). All data points are obtained from 3 independent experiments with 3 replicate wells per sample. We use the Student's t test method to analyze the results and obtain p values.
siRNA interference
SMARTpool siRNAs directed against human PRRX1 and non-targeting control were purchased from Dharmacon (Lafayette, CO). 50,000 FT282 cells stably overexpressing SOX18 were grown in 10 cm dishes. These were transfected with 50 mL of 5 mM PRRX1 or non-targeting siRNA using DharmaFECT3 transfection reagent (Dharmacon) according to manufacturer's instructions. 6 days after transfection, RNA was harvested from transfected cells and used for RT-qPCR, performed using TaqMan probes. Each experiment was performed three times independently, with technical triplicates. Paired Student's t tests were performed to obtain p values from comparing the mean expression value from each replicate experiment.
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-seq data processing and QC All data analysis was performed using 'R' and 'Bioconductor', and packages therein. RNaseq data for 394 HGSOC samples was obtained from The Cancer Genome Atlas (TCGA) data portal as protected data (raw sequencing, fastq files) and downloaded via CGHub's geneTorrent. Data was aligned to a reference genome (hg19) using STAR (Dobin et al., 2013) and quality control of aligned samples performed using RSeQC . GC bias and batch effect corrections were performed using EDASeq and 'sva' (Risso et al., 2011) . To adjust for batch effects we used an empirical Bayes framework (comBat), available in 'sva'. Genes absent in more than 80% of the samples were removed. Expression values correspond to the normalized adjusted values obtained from comBat.
Differential gene expression analyses
After normalization, the data matrix contained 21,071 genes. Parametric statistics (Student's t test) and supervised hierarchical clustering were performed to identify genes differentially expressed in pairwise comparisons of two groups of interest (OSEC, FTSEC and HGSOC). P values were adjusted using Benjamini-Hochberg step-up procedure.
Machine learning analyses
We applied a machine learning approach to define a probabilistic score associated to both normal cell types and infer tumor origins. A One-class classifier was selected as this method can handle non-traditional supervised scenarios where no negative class can be defined. The classifiers were implemented by the gelnet R-package version 1.2.1 (Sokolov et al., 2016b) . Data were mean centered considering all samples together, then each cell type used separately to train and test the models. To train the OSEC model we considered all OSEC samples, with a coefficient for the L1-norm penalty equal to 0 and coefficient for the L2-norm penalty equal to 1 as arguments of gelnet function. The training optimization is terminated after the desired tolerance is achieved (default 1e-5). We then evaluated the model performance through leave-one-out procedure where the left-out OSEC sample was mixed into FTSEC sample background. The accuracy was evaluated via the Area Under the ROC curve method, with 99% of OSEC samples correctly predicted, on average, and 97% of FTSECs correctly predicted. We then used the models to prediction cellular origins of 394 HGSOCs from TCGA. We took advantage of the fast gene set enrichment analysis (fgsea, version 1.2.1, http://bioconductor.org/ packages/release/bioc/html/fgsea.html) (Sergushichev, 2016) method to evaluate enrichment of clinical attributes across the tumor OCLR scores from both FTSEC and OSEC models. We applied the fgsea function with the parameter nperm equal to 10,000.
ChIP-seq data analysis
The AQUAS pipeline (https://github.com/kundajelab/chipseq_pipeline) was used to processed ChIP-seq data. Reads were aligned to the reference human genome (hg19), filtered by read quality and duplicate reads removed. macs2 (https://pypi.org/pypi/MACS2; Zhang et al., 2008) was used for peak calling. For the cell lines, two technical replicates were generated and the final peaks were obtained using a naive overlap approach, where the peaks are included if they overlap more than 50% between the two technical replicates. We have previously described H3K27ac ChIP-seq for immortalized OSEC and FTSEC lines (Coetzee et al., 2015) .
